What is the initial diagnostic work‑up and first‑line treatment for a treatment‑naïve adult with hepatitis C infection?

Initial Diagnostic Work-Up and First-Line Treatment for Hepatitis C

Initial Diagnostic Testing

Begin with anti-HCV antibody testing as the first-line screening test, followed immediately by reflex HCV RNA testing on the same specimen to confirm active infection. 1

Step 1: Anti-HCV Antibody Testing

• Order anti-HCV antibody testing using enzyme immunoassay (EIA) or chemiluminescence immunoassay as the initial screening test for all patients with suspected hepatitis C infection. 1, 2
• Third-generation EIAs (EIA-3) are preferred, offering sensitivity of 97.2–99% and specificity of 99.8–100% in immunocompetent individuals. 2
• Point-of-care rapid antibody tests provide comparable sensitivity and specificity to laboratory-based EIAs and can be used when immediate results are needed. 2

Step 2: Reflex HCV RNA Testing

• Order quantitative HCV RNA testing immediately on the same blood sample when anti-HCV is positive—this eliminates the need for a second venipuncture and is critical for care continuity. 1, 3, 2
• Use an FDA-approved quantitative HCV RNA assay with a lower limit of detection ≤15 IU/mL. 1, 4
• HCV RNA testing differentiates between current active infection (requiring treatment), past resolved infection (no treatment needed), and false-positive antibody results. 1, 3

Interpretation of Results

Anti-HCV positive + HCV RNA detected:

• Confirms current active chronic HCV infection requiring immediate linkage to specialized care and treatment. 3, 4

Anti-HCV positive + HCV RNA negative:

• Indicates either past resolved infection (spontaneous clearance occurs in 15–45% of cases) or false-positive antibody result. 3, 4
• Retest HCV RNA at 12 and 24 weeks later to confirm definitive clearance if recently acquired infection is suspected. 1
• Confirm the antibody result with an alternative assay platform if needed to distinguish false-positive from resolved infection. 3

Special Populations Requiring Modified Approach

Immunocompromised patients (HIV co-infection, solid-organ transplant recipients, hemodialysis patients, those on immunosuppressive therapy, hypogammaglobulinemia):

• Include HCV RNA testing as part of the initial evaluation regardless of antibody status, because antibody tests may be falsely negative despite active viremia. 1, 3, 2

Suspected acute hepatitis C or recent exposure (≤6 months):

• Include HCV RNA testing in the initial work-up because only ~50% of acute cases are anti-HCV positive at presentation. 3, 2
• HCV RNA becomes detectable 1–2 weeks after exposure, whereas antibodies appear at 8–9 weeks on average. 3
• Repeat HCV RNA testing even after an initial negative result if exposure was recent. 3

Individuals at risk for reinfection (people who inject drugs, men with HIV who have unprotected sex with men):

• Use HCV RNA testing (not antibody) for ongoing monitoring because antibodies remain persistently positive after prior infection. 3
• Test at least annually with HCV RNA. 3

Pre-Treatment Assessment

Once active HCV infection is confirmed (HCV RNA positive), perform the following baseline evaluation before initiating treatment:

Essential Laboratory Tests

• Quantitative HCV RNA (if not already performed as part of diagnosis) to establish baseline viral load. 4, 2
• HCV genotype and subgenotype determination (especially 1a vs 1b) to guide selection of direct-acting antiviral regimens. 1, 4
• Liver function panel: ALT, AST, bilirubin, albumin, platelet count, PT/INR. 3
• Assessment of liver fibrosis/cirrhosis using non-invasive methods (e.g., transient elastography, FIB-4, APRI) or liver biopsy to determine disease severity. 4

Co-Infection and Immunity Screening

• Screen for HIV, hepatitis B surface antigen/antibody, hepatitis A antibody to assess immunity and identify co-infections. 3, 4
• Screen for other sexually transmitted infections (syphilis, gonorrhea, chlamydia) in at-risk populations. 3
• Vaccinate against hepatitis A and B if non-immune; vaccination is safe during pregnancy when indicated. 3, 4

Referral

• Refer to a hepatology or infectious disease specialist experienced in HCV management for treatment planning. 3

First-Line Treatment

The goal of HCV therapy is to achieve sustained virological response (SVR), defined as undetectable HCV RNA (<15 IU/mL) at 12 weeks after treatment completion (SVR12), which corresponds to definitive cure in >99% of cases. 4, 2

Direct-Acting Antiviral (DAA) Regimens

• Use pangenotypic direct-acting antiviral (DAA) combination regimens as first-line treatment for all treatment-naïve adults with chronic HCV infection. 1, 4, 5
• Current DAA regimens target three key viral proteins: NS3/4A protease, NS5A protein, and NS5B RNA-dependent RNA polymerase. 5
• Combination of two or three DAAs can cure HCV infection in >90% of patients, including populations that were difficult to treat in the past. 5

Treatment Duration

• Treatment duration typically ranges from 8 to 12 weeks depending on the specific DAA regimen, genotype, and presence of cirrhosis. 1
• Patients with decompensated cirrhosis require specialized care and may need adjusted treatment regimens. 4

Treatment Monitoring

• Use the same quantitative HCV RNA assay throughout treatment to avoid variability between platforms. 3
• Confirm SVR by testing for undetectable HCV RNA at 12 weeks after treatment completion (SVR12). 4, 2

Post-Treatment Follow-Up

• Achieving SVR reduces all-cause mortality and markedly lowers the risk of progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. 3
• Patients with cirrhosis who achieve SVR should remain under surveillance for hepatocellular carcinoma every 6 months by ultrasound. 4
• Retest for HCV RNA at 48 weeks post-treatment to confirm cure in non-cirrhotic patients who achieve SVR. 4

Common Pitfalls to Avoid

• Do not assume a positive antibody test means active infection—approximately half of persons with reactive HCV antibody tests lack confirmatory HCV RNA testing, leading to misdiagnosis. 2
• Do not order supplemental antibody testing (RIBA) as the next step—HCV RNA testing is the preferred and more clinically useful confirmatory method. 3, 2
• Do not consider a single negative HCV RNA result conclusive when recent exposure or high clinical suspicion exists; repeat testing may be necessary. 3
• Do not rely solely on antibody testing in suspected acute infection—approximately 50% will be antibody-negative at presentation. 2
• Do not interpret viral load as a marker of disease severity—HCV RNA levels do not correlate with liver inflammation or fibrosis stage; liver fibrosis assessment requires non-invasive testing or biopsy. 3